Pharmacologic and clinical considerations of phosphodiesterase type 5 inhibitors and β-adrenergic receptor type 3 agonists for lower urinary tract symptoms and benign prostatic hyperplasia
Abstract
ABSTRACT Introduction Benign prostatic hyperplasia (BPH) is among the most common conditions affecting aging men, with resulting lower urinary tract symptoms (LUTS) impeding on quality of life. While many medication classes exist for treatment of LUTS secondary to BPH, their increasing prevalence in a growing and aging population begs the need for novel therapeutic avenues. Areas Covered This review covers the rationale for use of phosphodiesterase type 5 inhibitors and β-adrenergic receptor type 3 agonists in LUTS secondary to BPH. We evaluate their efficacy, pharmacokinetics, and safety, as well as potential drug-drug interactions. Finally, we evaluate their use in combination with standard-of-care medications, as well as their use in vulnerable populations. Included studies in this literature review and expert opinion were found using PubMed. Expert Opinion Mirabegron, vibegron, and tadalafil appear to be safe and efficacious medications in treatment of LUTS. Studies generally show favorable pharmacokinetics, and they can be used in combination with other BPH medications. Further studies are needed to understand the role of pharmacogenetics and use of these medications after surgical treatment. Thus, phosphodiesterase type 5 inhibitors and β-adrenergic receptor type 3 agonists are important tools in the urologist’s toolbox for treatment of BPH.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.